Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer
Prostate cancer (PCa) is one of the most frequently diagnosed malignancies, and the fifth leading cause of cancer related mortality in men. For advanced PCa, radical prostatectomy, radiotherapy, and/or long-term androgen deprivation therapy are the recommended treatment options. However, subsequent...
Main Authors: | Maria Frantzi, Marie C. Hupe, Axel S. Merseburger, Joost P. Schanstra, Harald Mischak, Agnieszka Latosinska |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/10/9/658 |
Similar Items
-
Promise and Implementation of Proteomic Prostate Cancer Biomarkers
by: Agnieszka Latosinska, et al.
Published: (2018-08-01) -
Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal Examination
by: Maria Frantzi, et al.
Published: (2023-02-01) -
Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation
by: Agnieszka Latosinska, et al.
Published: (2020-08-01) -
From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer
by: Ekaterina Nevedomskaya, et al.
Published: (2022-06-01) -
A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients’ Omics Signatures
by: Marika Mokou, et al.
Published: (2020-11-01)